Bah Humbug Vitamin D (12.20.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/fqx8wGLTqI https://t.co/5mwJx3ZN6u
Dr. John Cush @RheumNow( View Tweet )
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and… https://t.co/60vdbWLltB https://t.co/nY1CuJhKMb
Dr. John Cush @RheumNow( View Tweet )
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:
➡️ A. Ogdie: Preventing PsA
➡️ A. Kavanaugh: Biologic Therapies
➡️ K. Gordon: Head-to-Head Studies
Register now!
https://t.co/BTLmc8HSKY https://t.co/KVsLF3yOZx
Links:
Dr. John Cush @RheumNow( View Tweet )
Abuse of the Safety-Net 340B Drug Programs
Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing
Read Article
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/4TtnP5wGc4 https://t.co/RatBXPUk7a
Links:
Dr. John Cush @RheumNow( View Tweet )
Biosimilars Do Impact Biologic Drug Costs
MedPage Today
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.
Read Article
1st MTX use in 242 Italian pts w/ chronic inflam arthritis (54% RA, 33% PsA, 16% UA). Overall, survival of MTX at 24 months was 60%, (40% @48 mos, 20% @96 mos). MTX survival in RA & PsA equal, but superior to UA (undiff. arthritis) https://t.co/g4pZpVmTnM https://t.co/gcKWriqfhG
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes
Read Article
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/nDk8hPTlAu https://t.co/jnO5MijoGJ
Dr. John Cush @RheumNow( View Tweet )
Sex Differences in Psoriatic Arthritis
Dr. Catherine Bakewell shared key takeaways from a session presented Sunday morning by Dr. Laura Coates and Dr. Lihi Eder, as well as abstract 1709.
https://t.co/eKAzPSDQLH https://t.co/ACYMgVSW89
Dr. John Cush @RheumNow( View Tweet )
Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
Dr. Eric Dein talks with Dr. Ana-Marie Orbai about abstract 0600, Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis… https://t.co/HiqIly6Kii https://t.co/sFyqHE6ug1
Dr. John Cush @RheumNow( View Tweet )
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa
Dr. John Cush @RheumNow( View Tweet )
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
Dr. John Cush @RheumNow( View Tweet )
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy
Dr. John Cush @RheumNow( View Tweet )
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care
MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/94i7NZGSJH https://t.co/XiSLNaLuf9
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read Article
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.
Read Article
Will the Robots Save Ultrasound?
Ultrasound has a lot going for it in rheumatoid arthritis and psoriatic arthritis. It is free of ionizing radiation, yet can deliver helpful insights to the bedside, educating our patients along the way. As we seek to prognosticate more and… https://t.co/2JL2be3RMj https://t.co/4oQy6gcQVS
Dr. John Cush @RheumNow( View Tweet )
Infertility linked to post-childbrith onset of systemic autoimmune disease
EurekAlert!
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.
Read Article
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/21SHvGyUZH https://t.co/grDr5mfAzn
Dr. John Cush @RheumNow( View Tweet )
Biologic Monotherapy vs Combination with cDMARDs in PsA
https://t.co/MfqyD6hyOK https://t.co/fRJjOaJ9aT https://t.co/z8gutP79Ub
Links:
Dr. John Cush @RheumNow( View Tweet )
ACR24 IL-17 Topic Panel: Advancing Care with IL-17 Pathway Insights https://t.co/t9QQDYIrda
Links:
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
